HGH vs Vesilute
FDA Approved vs Moderate Research
synergistic Mechanism-based · 47% HGH and Vesilute work through complementary pathways. Growth hormone signaling supports tissue repair processes. A well-established combination in recovery protocols.
Molecular Data
HGH Vesilute
Weight 22,124 Da 262 Da
Half-life 3-4 hours (SC), 20-30 minutes (IV) Not established
Chain 191 amino acids 2 amino acids
Type Single-chain polypeptide with two disulfide bridges Dipeptide bioregulator
Key Benefits
HGH
01 Improved body composition (increased lean mass, decreased fat)
02 Enhanced bone mineral density
03 Improved lipid profile
04 Increased exercise capacity
05 Better quality of life and mood
06 Skin, hair, and nail improvements
07 Enhanced recovery and healing
Vesilute
01 Supports bladder and urinary tract function
02 May improve prostate health in men
03 Regulates smooth muscle function
04 Enhances pelvic tissue blood flow
05 Supports cellular regeneration
06 Part of comprehensive Khavinson bioregulator protocols
07 Well-tolerated in research
08 Oral bioavailability as small dipeptide
Dosing Protocols
HGH
1-4 IU daily (0.33-1.33mg); start low and titrate up / Once daily or split into 2 doses (morning and evening)
Medical GHD (Starting) 0.15-0.3mg/day (0.5-1 IU) Once daily
Medical GHD (Maintenance) 0.4-0.8mg/day (1.2-2.4 IU) Once daily
Anti-Aging/Wellness 1-2 IU/day (0.33-0.67mg) Once daily
Body Recomposition 2-4 IU/day (0.67-1.33mg) Once or twice daily
Performance (Higher Risk) 4-8 IU/day (1.33-2.67mg) Split twice daily
Vesilute
10-20 mg per day / Daily for 10-20 consecutive days (Khavinson bioregulator cycle)
Standard protocol 10-20 mg Daily for 10-20 days
Maintenance 20 mg 2-3 cycles yearly
Side Effects
HGH
Water retention and fluid accumulation
Joint pain and stiffness
Carpal tunnel syndrome (usually resolves with dose reduction)
Headaches
Numbness/tingling in hands
Vesilute
Generally well-tolerated
Injection site reactions (mild, if injectable)
Minimal reported side effects
Contraindications
Active cancer (may accelerate tumor growth)
Acute critical illness (increased mortality in ICU patients)
Closed epiphyses in children (for growth promotion)
Pregnancy/breastfeeding
Known hypersensitivity to peptide components
Active urinary tract infection (treat first)
Pregnancy or breastfeeding
Prostate cancer (consult physician)
Research Evidence
HGH Vesilute
Status FDA Approved Moderate Research
References 4 studies 3 studies
Latest 2024 —
FDA Approved Yes No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.